

# Echocardiography in Pulmonary Arterial Hypertension in Congenital Heart Disease

Mark K. Friedberg, MD



**SickKids<sup>®</sup>**

**The Labatt Family  
Heart Centre**

# Outline

- Introduction
- Congenital lesions that cause PAH (increased pulmonary pressures)
- Assessment of RV function in PAH
- Evaluation of ventricular-ventricular interactions

# PAH in CHD

## Definition

PAH: mean pulmonary artery pressure (PAP)  $>25$  mm Hg at rest or  $>30$  mm Hg during exercise, with a left atrial pressure  $<15$  mm Hg and a PVR  $<3$  Wood units.

- Common (15% of the CHD population is thought to develop PVD; including patients whose PVR exceeds systemic vascular resistance with reversed shunting (Eisenmenger syndrome).
- Pre-operative (usually) increased shunt.
- Post-operative (endothelial dysfunction).

## Shunts

- VSD
- ASD
- AVSD
- PDA
- Aorta-pulmonary window

## Lt obstructive lesions


- Pulmonary vein stenosis
- Cor triatriatum
- Supramitral ring
- Mitral stenosis
- Shones
- Aortic coarctation

**Pulmonary venous hypertension**


## Clinical questions to be answered by echo:

- Severity of pulmonary hypertension
  - Pulmonary artery systolic and diastolic pressures
- Underlying lesions / shunting across intra-cardiac communication
- Associated lesions
- Right and left ventricular function
- Right ventricular hypertrophy
- Tricuspid regurgitation



# Shunt lesions






# Shunt lesions



# Perimembranous VSD



# Perimembranous VSD




# Eisenmenger's syndrome

- Irreversible pulmonary vascular disease from a systemic-to-pulmonary communication (ASD, non-restrictive VSD, non-restrictive PDA, atrioventricular septal defect, aortopulmonary window, surgical systemic-to-pulmonary shunt).
- An initial  $L > R$  shunt reverses direction following an increase in PVR.

# Evaluating worsening in Eisenmenger

- Signs of impending RV failure:
  - RV enlargement and dysfunction.
  - Septal flattening in diastole as well as systole.
  - Worsening tricuspid regurgitation
    - increasing afterload
    - annular dilatation
    - RV dysfunction
  - Right atrial enlargement
    - TR
    - impaired RV compliance.




Elevated PAp

Increased  
flow


Increased  
PVR

# 5 months, AVSD


## Pre-op




## Post bypass TEE





## Post bypass TEE



## Post bypass TEE




# Infant, AVSD, post-op cant wean from ventilator




# Ill neonate, pre-ECMO echo







# Pulmonary vein stenosis





# Cor tritriatum





# 9 months, tachypnea



# Supra-mitral ring



# Infant, Failure to thrive




JPEG  
140 bpm

JPEG  
133 bpm

0.1%  
C 50  
P Off  
Pen




JPEG  
135 bpm




JPEG  
147 bpm




# Infant, Failure to thrive






# At Follow-up








# Borderline LV-Irreversible PAH?









# Aortic coarctation



# Assessment of RV function




# RV structure



Anderson, Semin Thorac Cardiovasc Surg  
Pediatr Card Surg Ann 2007 10:76

Chin, Coronary Artery Disease  
2005, 16:13-18

# The RV does not handle afterload well



# What should we measure?

Table 1

Echocardiographic measurements used in pulmonary hypertension [2]

*Qualitative assessment*

Enlarged right atrium and ventricle\*

Right ventricle hypertrophy\*

D-shaped left ventricular cavity with flattening of the interventricular septum in systole\*

Diminished/absent atrial wave of pulmonary valve

Mid systolic closure or notching of pulmonary valve

*Hemodynamic assessment*

Tricuspid regurgitation velocity\*

Pulmonary regurgitation velocity\*

Right ventricular outflow tract flow acceleration time

Pulmonary artery systolic flow acceleration time

Right ventricular ejection time

Right ventricular index of myocardial performance

Timing of mid systolic deceleration of right ventricular ejection

Right ventricular long axis function (marker of overall right ventricular systolic function)

\* Minimal data set required for echocardiographic evaluation of pulmonary arterial hypertension.

Additional echocardiographic measures described in the literature

RV end-diastolic area index

Right atrial end-systolic area index

RV area change (percentage)

Eccentricity index

Severity of TR/right atrial ratio

Stroke volume

Cardiac index

Pericardial effusion size

Doppler index of global RV dysfunction as suggested by Tei et al.

# Assessment of RV function by echo remains difficult




- No axis of symmetry (complicates geometric modeling).
- Endocardial delineation is difficult (prominent endocardial trabeculations)
- Retrosternal location limits acoustic access.

# 2D Assessment


# 'Eyeball' assessment still most prevalent method




# 2D assessment



### Eccentricity index




### Right atrial size




# Right atrial size

Survival free from TX for different values of RAS



# Pericardial effusion




Bustamante-Labarta, JASE 2002;15:1160

Douglas, Circulation 1989;80:353


# Annular Motion

# Tricuspid annular plane systolic excursion (TAPSE)



Age	n	TAPSE (cm)					BSA (m <sup>2</sup> )			Indexed TAPSE mean/BSA mean
		Mean	Bounds for z-score ranges		±3 SD (99%)	Mean	Minimum	Maximum		
			±2 SD (95%)	±1 SD (68%)						
0-30 d	41	0.91	0.68	1.15	0.56	1.26	0.22	0.14	0.28	4.13
1-3 mo	45	1.14	0.85	1.42	0.71	1.56	0.29	0.12	0.54	3.93
4-6 mo	20	1.31	1.01	1.65	0.86	1.77	0.34	0.26	0.41	3.85
7-12 mo	22	1.44	1.13	1.77	0.97	1.91	0.40	0.31	0.47	3.6
1 y	25	1.55	1.25	1.88	1.10	2.00	0.47	0.3	0.69	3.29
2 y	39	1.65	1.36	1.94	1.22	2.09	0.53	0.4	0.62	3.11
3 y	27	1.74	1.48	2.02	1.35	2.14	0.63	0.52	0.77	2.76
4 y	47	1.82	1.56	2.07	1.43	2.20	0.70	0.6	0.91	2.6
5 y	29	1.87	1.60	2.13	1.47	2.26	0.77	0.63	0.99	2.42
6 y	41	1.90	1.62	2.18	1.48	2.33	0.82	0.46	1.06	2.31
7 y	32	1.94	1.64	2.25	1.49	2.39	0.94	0.75	1.17	2.06
8 y	23	1.97	1.67	2.28	1.52	2.43	0.97	0.79	1.39	2.03
9 y	20	2.01	1.73	2.30	1.58	2.44	1.00	0.8	1.32	2.01
10 y	27	2.05	1.79	2.31	1.65	2.46	1.15	0.82	1.54	1.78
11 y	25	2.10	1.83	2.36	1.69	2.50	1.28	1.06	1.55	1.64
12 y	18	2.14	1.84	2.43	1.68	2.60	1.39	1.06	1.67	1.53
13 y	20	2.20	1.85	2.54	1.68	2.71	1.48	1.03	1.87	1.48
14 y	35	2.26	1.87	2.65	1.68	2.84	1.55	1.11	1.93	1.45
15 y	25	2.33	1.93	2.75	1.74	2.92	1.59	1.32	1.96	1.46
16 y	34	2.39	1.98	2.78	1.78	3.01	1.66	1.3	2.04	1.43
17 y	27	2.45	2.04	2.88	1.83	3.06	1.77	1.43	2.06	1.38
18 y	21	2.47	2.05	2.91	1.84	3.10	1.79	1.34	2.25	1.37

# TAPSE correlates with RV EF



López-Candales, Am J Cardiol 2006;98:973






FIGURE 3. Correlation of the RV ejection fraction (EF) by MRI with long-axis ventricular function by M-mode imaging.

Lissin, Am J Cardiol 2004;93:654–657


# What is the value of TAPSE ?



SVI	37 ml/m <sup>2</sup>
CI	2.9 l/min/m <sup>2</sup>
RAP	11 mmHg
mPAP	44 mmHg
PVR	6.5 mmHg/l/min




SVI	24 ml/m <sup>2</sup>
CI	2.0 l/min/m <sup>2</sup>
RAP	10 mmHg
mPAP	50 mmHg
PVR	11.0 mmHg/l/min




Ability of TAPSE to predict RV stroke volume index of 29 ml/m<sup>2</sup>.

# What is the value of TAPSE ?



TAPSE $\geq$ 1.8 cm (N)	17	17	16	15	15
TAPSE < 1.8 cm (N)	30	23	18	16	13

# A smaller TAPSE may originate from RV mechanical delay




Univariate analysis of RV mechanical delay to other clinical and echocardiographic variables in patients with abnormal RV performance


Variable	r Value	p Value
Age (yrs)	0.06	NS
Heart rate (beats/min)	0.05	NS
QRS duration (ms)	0.67	<0.05
Systolic pulmonary artery pressure (mm Hg)	0.67	<0.05
RV end-diastolic area (cm)	0.73	<0.05
RV end-systolic area (cm)	0.81	<0.05
RV fractional area change (%)	-0.89	<0.05
Eccentricity index	0.75	<0.05
RV myocardial performance index	0.77	<0.05
Vena contracta width	0.63	<0.05
RV free wall peak strain (%)	0.58	<0.05


# LV function also influences TAPSE

(A)  $\downarrow$  Coronary perfusion pressure +  $\uparrow$   $O_2$  Demand =  $\downarrow$  Supply/Demand




(B)  $\uparrow\uparrow$  RV Distention &  $\downarrow$  LV Filling =  $\downarrow$  Cardiac Output






# Tricuspid velocities



Age group	N	E'-wave velocity	A'-wave velocity	S'-wave velocity
Tricuspid annular				
<1 y	63	13.8 ± 8.2 (11.7-15.9)	9.8 ± 2.4 (9.1-10.5)	10.2 ± 5.5 (8.8-11.7)
1-5 y	68	17.1 ± 4.0† (16.1-18.1)	10.9 ± 2.7 (10.2-11.6)	13.2 ± 2.0† (12.7-13.7)
6-9 y	55	16.5 ± 3.0 (15.7-17.4)	9.8 ± 2.7 (9.0-10.6)	13.4 ± 2.0 (12.8-14.0)
10-13 y	58	16.5 ± 3.1 (15.7-17.4)	10.3 ± 3.4 (9.3-11.2)	13.9 ± 2.4 (13.2-14.5)
14-18 y	81	16.7 ± 2.8 (16.0-17.3)	10.1 ± 2.6 (9.5-10.7)	14.2 ± 2.3 (13.7-14.7)
Total	325	16.1 ± 4.7 (15.6-16.7)	10.2 ± 2.8 (9.9-10.5)	13.0 ± 3.4 (12.6-13.4)


# Tissue Displacement (tracking)




# Assessment of myocardial function

# Assessing Myocardial Deformation


$$S = \frac{l - l_0}{l_0} = \frac{\Delta l}{l_0}$$



# RV strain by speckle tracking




# Strain correlates with stroke volume



\*SV determined at cath

# RV strain is influenced by afterload



# Assessment of regional RV function by strain





Figure 1 Right ventricular strain rate and strain profiles from basal and apical segments in control subject (A) and patient with pulmonary hypertension (B). PVc, Pulmonary valve closure; PVo, pulmonary valve opening.

\*No significant correlations between deformation and NYHA or 6-min walk test.

Dambauskaite, J Am Soc Echocardiogr 2007;20:1172

# RV myocardial function







Table 2


Invasive hemodynamic and echocardiographic data before and after epoprostenol infusion

Variable	Before Epoprostenol (n = 12)	Peak Epoprostenol (n = 12)
RV peak systolic pressure (mm Hg)	74.5 ± 20.0	65.7 ± 19.3*
Pulmonary vascular resistance (Wood units)	18.3 ± 12.2	11.4 ± 10.3*
RVSVI (ml/m <sup>2</sup> )	27.1 ± 13.5	35.7 ± 15.2*
Isovolumic myocardial acceleration (m/s <sup>2</sup> )	1.6 ± 1.0	1.6 ± 1.4
RV peak systolic velocity (cm/s)	5.0 ± 1.9	6.1 ± 2.2*
RV peak systolic displacement (mm)	8.8 ± 4.5	11.1 ± 5.2*
RV peak systolic strain rate (1/s)	-1.2 ± 0.9	-1.5 ± 0.8
RV peak systolic strain (%)	-13.8 ± 8.5	-17.6 ± 9.1*

\* p ≤ 0.05.


Urheim, Relation of Tissue Displacement and Strain to Invasively Determined Right Ventricular Stroke Volume, **AJC 2005;96:1173**

# Assessing RV End-systolic Elastance




*Redington et al. Br Heart J 1988;58:23-8*


# Strain rate



# Isovolumic acceleration



# Isovolumic acceleration is relatively load independent




# 3D Assessment

# 3D assessment of RV function


## Echocardiographic Assessment of the Right Ventricular Response to Hypertension in Neonates on the Basis of Average-shaped Contraction Models

Edward N. Marcus, MSc, Ricardo A. Munoz, MD, Renee Margossian, MD, Steven D. Colan, MD, and David L. Wessel, MD, *Boston, Massachusetts; and Miami, Florida*


(A) Alignment




(B) Reconstruction




(C) 3D Shape



# 3D RV function



# MPI for RV function in CHD



“a” is duration of tricuspid valve regurgitation

“b” is RV ejection time

# Loading and MPI

**TABLE 3** Comparison of Doppler Time Intervals: Pre- Versus Postoperative Atrial Septal Defect

	ASD Group I		ASD Group II	
	Pre (n = 16)	Post (n = 16)	Pre (n = 16)	Post (n = 16)
Heart rate (beats/min)	97 (17)	107 (28) <sup>†</sup>	74 (16)	85 (17)*
RV MPI	0.34 (0.05)	0.33 (0.03) <sup>†</sup>	0.36 (0.03)	0.35 (.03) <sup>†</sup>
RV ICT (ms)	35 (13)	24 (9)*	45 (14)	30 (9)*
RV IRT (ms)	62 (14)	55 (13) <sup>†</sup>	76 (12)	64 (10)*
RV ejection time (ms)	282 (22)	236 (29)*	310 (38)	297 (67) <sup>†</sup>

\*p <0.05 compared with preceding column; <sup>†</sup>p = NS compared with preceding column.


**TABLE 4** Comparison of Doppler Time Intervals: Pre- Versus Postintervention in Pulmonary Stenosis

	Preintervention (n = 21)	Postintervention (n = 21)
Heart rate (beats/min)	89 (19)	99 (32) <sup>†</sup>
Peak gradient (mm Hg)	63 (29)	24 (14)*
RV MPI	0.32 (.06)	0.33 (0.06) <sup>†</sup>
RV ICT (ms)	63 (33)	57 (22) <sup>†</sup>
RV IRT (ms)	70 (19)	63 (21) <sup>†</sup>
RV ejection time (ms)	280 (57)	264 (61) <sup>†</sup>

\*p <0.05 compared with preceding column; <sup>†</sup>p = NS compared with preceding column.


# Problems with MPI

- Can't assess inflow and outflow simultaneously in RV
- Therefore HR has to be similar in both measurements
- ICT is short in the normal RV -> IRT becomes more important (itself an independent index)
- Doesn't tell you what is wrong



# PHT: A BIVENTRICULAR DISEASE


## Physiology



**Symptomatic deterioration when  $PVR > SVR$**

Courtesy Dr Andrew Redington



# RV ejection



# Ventricular interactions


**Tricuspid valve**

**Mitral inflow**




**Increased duration of RV systole  
leads to reduced LV preload**



# The S/D Duration ratio




# The S/D ratio: Dilated Cardiomyopathy






# SD ratio in the RV



# SD ratio in PHTN





# Summary

- Assessment of RV function is a central component in the evaluation, management and follow-up of children with CHD and pulmonary vascular disease.
- Assessment of RV function provides prognostic information.
- Echo remains the mainstay of clinical imaging in this condition, but has important limitations.
- Newer methods (based on older and newer technology) can be combined with conventional assessment to provide a more comprehensive evaluation.
- Further validation of the newer methods in clinical practice is needed.



Thank  
You